The treatment of osteosarcoma, the most common tumor of bone, is challenging. An MD Anderson study found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness.
The preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine.
Although osteosarcoma is a relatively rare cancer, it is a leading disease-related...
An MD Anderson study may help researchers predict which patients with non-small cell lung cancer will respond to checkpoint blockade therapy...
Patterns in how genes express themselves may help doctors personalize treatment for glioblastoma, the most deadly of brain cancers, according...
A study of high-grade ovarian cancer has shown the enzyme protein kinase C iota (PRKCI) to be an ovarian oncogene, suggesting PRKCI inhibition as a possible new therapeutic area of study for this deadly disease. The findings were published onlin in Genes & Development.
Ovarian cancer is the leading cause of death by cancers of the female reproductive system. Each year, approximately 22,000 women are diagnosed with the disease...
This fall, experts from MD Anderson, the American Dental Association (ADA), the Centers for Disease Control and Prevention and the University...
MD Anderson Cancer Center again has been ranked No. 1 for cancer care by U.S. News & World Report’s annual “Best Hospitals” survey...
For patients with advanced, inoperable stage 3 lung cancer, chemotherapy and a specialized form of radiation treatment known as proton...
Since 2006, MD Anderson’s Tobacco Treatment Program (TTP) has been providing tobacco cessation services to patients and employees seeking...
A practice-changing clinical trial conceived and led by MD Anderson investigators showed that metastatic colorectal cancer patients with a...
Two challenges in treating patients with estrogen-positive breast cancer (ER+) have been the inability to predict who will respond to standard...